CDT and Manoira Evaluate Assets for Animal Health Products

CDT Equity Inc. has entered into an evaluation agreement with Manoira Corporation to assess the potential of CDT clinical-stage assets to enhance Manoira’s forthcoming animal health products, according to Manilatimes.

Manilatimes reported that Manoira is a specialty animal health company. The agreement covers AZD1656, including certain proprietary cocrystal derivatives, and AZD5904.

Agreement centers on asset evaluation

According to Manilatimes, the companies will explore the potential of the named CDT assets in relation to Manoira’s forthcoming animal health products. The announced arrangement is an evaluation agreement.

The report identifies AZD1656 and AZD5904 as clinical-stage assets. It also specifies that certain proprietary cocrystal derivatives of AZD1656 are included in the evaluation.

CDT announced the agreement with Manoira on Oct. 27, 2026, Manilatimes reported. The announcement was issued from Naples, Fla. and Cambridge, United Kingdom.

Named assets in the collaboration

• AZD1656
• Certain proprietary cocrystal derivatives of AZD1656
• AZD5904

For veterinary and animal health sales professionals, the announcement identifies a partnership involving a specialty animal health company and clinical-stage assets being assessed for potential product enhancement. The stated focus is Manoira’s forthcoming animal health products.

Manilatimes did not provide further detail in the report on a named indication, species, market segment, development plan, product timing, or the outcome of the evaluation. The announcement describes the companies’ intent to assess potential rather than a completed product enhancement.

The partnership brings CDT’s named assets into an evaluation process with Manoira. As reported by Manilatimes, the companies are exploring whether those assets may enhance Manoira’s forthcoming animal health products.

What the announcement states

CDT is identified in the report as CDT Equity Inc., and Manoira is identified as Manoira Corporation. The companies’ agreement concerns assessment of the potential of the assets listed in the announcement.

The published announcement does not state that the evaluation has produced an outcome. It also does not name a resulting animal health product. The available report instead frames the work around exploring potential ahead of Manoira’s forthcoming product activity.